(A) Primary patient AML bone marrow samples were assessed by western immunoblotting for the expression of EGFR protein. An EGFR-expressing positive control HCC827, and an EGFR-non-expressing negative control, MV4-11, were included. Actin was evaluated as a loading control.
(B) Primary patient AML peripheral blood mononuclear cells were assessed in the same manner as in (A) for expression of EGFR protein.
(C) RT-PCR was performed to evaluate for EGFR transcript expression in primary patient AML cells. GAPDH was amplified as a control gene and an EGFR-expressing positive control, HCC827, and an EGFR-non-expressing negative control, MV4-11, were included.